

DOCKET NUMBER  
PETITION RULE PRM 35-9  
(54 FR 38239)



132

Abdominal Radiology  
General Radiology  
Mammography  
Musculoskeletal Radiology  
(904) 395-0101  
Computerized Tomography  
Interventional and Vascular Radiology  
Neuroradiology  
Ultrasound  
(904) 395-0104

DEPARTMENT OF RADIOLOGY

University of Florida  
College of Medicine '89 NOV -1 P4 132  
Box J-374  
Gainesville, Florida 32610  
Telephone: (904) 395-0290

Magnetic Resonance Imaging  
(904) 395-0106  
Radiation Physics  
Magnetic Resonance Physics  
(904) 395-0293  
Nuclear Medicine  
(904) 395-0106  
Pediatric Radiology  
(904) 395-0102

October 26, 1989

Secretary of the Commission  
U.S. Nuclear Regulatory Commission  
Docketing and Service Branch, Docket #PRM-35-9  
Washington, DC 20555

Dear Mr. Secretary:

I am writing to express by strong support for the Petition for Rulemaking filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. I am a practicing Nuclear Medicine physician at the University of Florida College of Medicine in Gainesville, Florida. I am deeply concerned over the revised 10 CFR 35 regulations (effective April, 1987) governing the medical use of byproduct material as they significantly impact my ability to practice high-quality Nuclear Medicine/Nuclear Pharmacy and are preventing me from providing optimized care to individual patients.

For example, the package insert for Ceretec requires the performance of chromatography prior to injection of a patient. The chromatography takes approximately 15 to 20 minutes. The product is only good for 30 minutes. This gives you 10 minutes to inject an agent, which has deteriorated by two thirds of the allowable amount. This typically results in inferior quality images at best. Injecting the patient as soon as possible after preparation, and starting the chromatography at the same time, results in excellent quality studies, which do not need to be repeated, thereby improving patient care. Results of the chromatography are still available, and reflect more accurately the state of this very delicate compound at the time of injection. Radiation exposure to the patient is also reduced since the study will not need to be repeated.

The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of the approved drugs, and actively discourages the submission of physician-sponsored IND's that describe new indications for approved drugs. The package insert was never intended to prohibit physicians from deviating from it for other indications; on the contrary, such deviation is necessary for growth in developing new diagnostic and therapeutic procedures. In many cases, manufacturers will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Currently, the regulatory provisions in Part 35 (35.100, 35.200, 35.300 and 33.17(a)(4)) do not allow practices which are legitimate and legal under FDA regulations and State medicine and pharmacy laws. These regulations therefore inappropriately interfere with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

Finally, I would like to point out that highly restrictive NRC regulations will only jeopardize public health and safety by: restricting access to appropriate Nuclear Medicine procedures; exposing patients to higher radiation absorbed doses from alternative legal, but non-optimal, studies; and exposing hospital personnel to higher radiation absorbed doses because of unwarranted, repetitive procedures. The NRC should not strive to construct prescriptive regulations to cover all aspects of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, State Boards of Pharmacy, State Boards of Medical Quality Assurance, the Joint Commission on Accreditation of Healthcare Organizations, radiation safety committees, institutional Q/A review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well-trained to administer and prepare these materials.


B9110BC073 091026  
FDR PRM  
35-9 PDR

PS10

Since the NRC's primary regulatory focus appears to be based on the unsubstantiated assumption that misadministrations, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat to the public health and safety, I strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the NCRP, to assess the radiobiological effects of misadministrations from Nuclear Medicine diagnostic and therapeutic studies. I firmly believe that the results of such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost-effective in relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the ACCNP/SNM Petition for Rulemaking as expeditiously as possible.

Sincerely,



Edward V. Staab, M.D.  
Professor and Chairman  
University of Florida College of Medicine

EVS:kmm